To assess the therapeutic potential of CD244-deficient macrophages in the preclinical setting, we performed adoptive transfer of CD244−/− BMDM in the presence of an anti-PD-L1 antibody to B16 melanoma-bearing WT mice. This evidence concerns the gene CD244 and melanoma.